Nimbus Therapeutics

At Nimbus, our mission is to develop breakthrough medicines for patients through precision small molecule design. We pride ourselves on our nimbleness, our expertise, our focus on collaboration, and our rich and supportive culture. With our approach, we have successfully advanced four programs into the clinic—and we’re enthusiastically working towards expanding on that success as we continue to focus on bringing truly novel medicines to those who can benefit the most.Nimbus Therapeutics is a clinical-stage, structure-based drug discovery company developing novel small molecule medicines designed to act against well-validated but difficult-to-drug targets implicated in multiple human diseases. The company advances promising research based on a unique strategy that combines leading-edge computational technologies with a tailored array of machine learning-based predictive modeling approaches. Nimbus' pipeline includes a clinical-stage HPK1 inhibitor for the treatment of cancer (NCT05128487), as well as a diverse portfolio of preclinical programs focused on cancer, including a WRN program for MSI-H cancers, autoimmune conditions, and metabolic diseases.